J. Mendelsohn

Oncology · 2000–2019

A researcher in the Science corpus: 6 papers; trusts 1 researcher and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 57 citations into it; #940 of 1,698 by trust here, #845 by citations
• Molecular Biology — 36 citations into it; #11,639 of 17,773 by trust here, #10,193 by citations
• Radiology, Nuclear Medicine and Imaging — 14 citations into it; #2,061 of 3,265 by trust here, #1,253 by citations

Whom J. Mendelsohn trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Baselga
2. Fortunato Ciardiello
3. H. Lane
4. William Pao
5. Y. Yarden

Who trusts J. Mendelsohn overall

1. William Pao
2. J. Baselga
3. Thomas Holbro
4. M. Moasser
5. M. Lacouture
6. C. Blobel
7. K. Imai
8. P. Roberts
9. R. Agarwal
10. S. Goswami

Papers from J. Mendelsohn's perspective

Ordered by how strongly the researchers J. Mendelsohn trusts endorse each paper. Same corpus, a different order for every researcher.

1. The ErbB signaling network: receptor heterodimerization in development and cancer (EMBO Journal)
2. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing (Nature Biotechnology)
3. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (Journal of the American Medical Association (JAMA))
4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
5. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
6. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
7. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
8. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
9. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) (Cancer Research)
10. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. (Cell)

Their papers

• The EGF receptor family as targets for cancer therapy (2000) — 1,389 citations
• Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) — 375 citations
• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) — 501 citations
• Epidermal growth factor receptor targeting in cancer. (2006) — 740 citations
• Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. (2003) — 1,295 citations
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. (2000) — 772 citations